Erratum: Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: A prospective single-arm monocentric phase-II study (RNOP-05) (Journal of Neuro-Oncology (2011) 104 (801-809) DOI:10.1007/s11060-011-0548-y);Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: A prospective single-arm monocentric phase-II study (RNOP-05)

Journal of Neuro-Oncology

Volumn 104, Issue 3, 2011, Pages 801-809

  Grauer, Oliver ^a   Pascher, Christina ^a   Hartmann, Christian ^b,c   Zeman, Florian ^a   Weller, Michael ^d   Proescholdt, Martin ^a   Brawanski, Alexander ^a   Pietsch, Thorsten ^e   Wick, Wolfgang ^c   Bogdahn, Ulrich ^a   Hau, Peter ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e UNIVERSITY OF BONN   (Germany)

Author keywords

13 cis retinoic acid; 1p 19q co deletion; Anaplastic glioma; IDH1; MGMT; Temozolomide

Indexed keywords

ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; ISOTRETINOIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; AGED; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; BRAIN SURGERY; CANCER ADJUVANT THERAPY; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CHROMOSOME 19Q; CHROMOSOME 1P; CLINICAL ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DNA METHYLATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DRY EYE; DRY SKIN; EYE TOXICITY; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; GENE DELETION; GENE MUTATION; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HYPERTRIGLYCERIDEMIA; INSOMNIA; LEUKOCYTE COUNT; LEUKOPENIA; LIP DISEASE; LUNG EMBOLISM; MALE; MENSTRUAL IRREGULARITY; METABOLIC DISORDER; MOOD DISORDER; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROTOXICITY; OLIGODENDROGLIA; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PROGNOSIS; PROGRESSION FREE SURVIVAL; PRURITUS; SIDE EFFECT; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; SKIN TOXICITY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE COUNT; THROMBOSIS; UROGENITAL TRACT DISEASE; VAGINAL DRYNESS; VISUAL DISORDER; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 80052617976     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-011-0742-y     Document Type: Erratum

References (39)

1. H Bouterfa T Picht D Kess C Herbold E Noll PM Black K Roosen JC Tonn 2000 Retinoids inhibit human glioma cell proliferation and migration in primary cell cultures but not in established cell lines Neurosurgery 46 419 430 10690732 10.1097/00006123-200002000-00029 1:STN:280:DC%2BD3c7lt1Gqsw%3D%3D (Pubitemid 30094480)
2. SL Costa E Paillaud C Fages C Rochette-Egly JL Plassat H Jouault A Perzelova M Tardy 2001 Effects of a novel synthetic retinoid on malignant glioma in vitro: inhibition of cell proliferation, induction of apoptosis and differentiation Eur J Cancer 37 520 530 11267863 10.1016/S0959-8049(00)00430-5 1:CAS:528:DC%2BD3MXhvFKju7g%3D (Pubitemid 32232118)
3. E Paillaud S Costa C Fages JL Plassat C Rochette-Egly C Monville M Tardy 2002 Retinoic acid increases proliferation rate of GL-15 glioma cells, involving activation of STAT-3 transcription factor J Neurosci Res 67 670 679 11891779 10.1002/jnr.10110 1:CAS:528:DC%2BD38XisVKnsbk%3D (Pubitemid 34207680)
4. A Das NL Banik SK Ray 2008 Retinoids induced astrocytic differentiation with down regulation of telomerase activity and enhanced sensitivity to taxol for apoptosis in human glioblastoma T98G and U87MG cells J Neurooncol 87 9 22 17987264 10.1007/s11060-007-9485-1 1:CAS:528:DC%2BD1cXivFygsbs%3D
5. B Campos F Wan M Farhadi A Ernst F Zeppernick KE Tagscherer R Ahmadi J Lohr C Dictus G Gdynia SE Combs V Goidts BM Helmke V Eckstein W Roth P Beckhove P Lichter A Unterberg B Radlwimmer C Herold-Mende 2010 Differentiation therapy exerts antitumor effects on stem-like glioma cells Clin Cancer Res 16 2715 2728 20442299 10.1158/1078-0432.CCR-09-1800 1:CAS:528:DC%2BC3cXlvF2iu7o%3D
6. FL Meyskens Jr. GE Goodman DS Alberts 1985 13-cis-Retinoic acid: pharmacology, toxicology, and clinical applications for the prevention and treatment of human cancer Crit Rev Oncol Hematol 3 75 101 3893773 10.1016/S1040-8428(85)80040-8 (Pubitemid 15021980)
7. F Le Doze D Debruyne F Albessard L Barre GL Defer 2000 Pharmacokinetics of all-trans retinoic acid, 13-cis retinoic acid, and fenretinide in plasma and brain of Rat Drug Metab Dispos 28 205 208 10640519 1:CAS:528: DC%2BD3cXot1WhsA%3D%3D (Pubitemid 30069005)
8. WK Yung AP Kyritsis MJ Gleason VA Levin 1996 Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid Clin Cancer Res 2 1931 1935 9816151 1:CAS:528:DyaK2sXitlKrsQ%3D%3D (Pubitemid 27006624)
9. C Wismeth P Hau K Fabel U Baumgart B Hirschmann H Koch T Jauch O Grauer L Drechsel A Brawanski U Bogdahn A Steinbrecher 2004 Maintenance therapy with 13-cis retinoid acid in high-grade glioma at complete response after first-line multimodal therapy-a phase-II study J Neurooncol 68 79 86 15174524 10.1023/B:NEON.0000024748.26608.2f (Pubitemid 39137353)
10. WK Yung MD Prados R Yaya-Tur SS Rosenfeld M Brada HS Friedman R Albright J Olson SM Chang AM O'Neill AH Friedman J Bruner N Yue M Dugan S Zaknoen VA Levin 1999 Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group J Clin Oncol 17 2762 2771 10561351 1:CAS:528: DyaK1MXmtlWru7s%3D (Pubitemid 29415233)
11. WK Yung RE Albright J Olson R Fredericks K Fink MD Prados M Brada A Spence RJ Hohl W Shapiro M Glantz H Greenberg RG Selker NA Vick R Rampling H Friedman P Phillips J Bruner N Yue D Osoba S Zaknoen VA Levin 2000 A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse Br J Cancer 83 588 593 10944597 10.1054/bjoc.2000.1316 1:CAS:528:DC%2BD3cXmvVCgsrs%3D (Pubitemid 30636298)
12. S Chibbaro L Benvenuti A Caprio S Carnesecchi F Pulera F Faggionato D Serino C Galli M Andreuccetti N Buxton R Gagliardi 2004 Temozolomide as first-line agent in treating high-grade gliomas: phase II study J Neurooncol 67 77 81 15072451 10.1023/B:NEON.0000021728.36747.93 1:STN:280: DC%2BD2c7nsl2jtQ%3D%3D (Pubitemid 38418252)
13. JM Reid DC Stevens J Rubin MM Ames 1997 Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer Clin Cancer Res 3 2393 2398 9815639 1:CAS:528:DyaK1cXisV2qsA%3D%3D (Pubitemid 28133160)
14. S Ostermann C Csajka T Buclin S Leyvraz F Lejeune LA Decosterd R Stupp 2004 Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients Clin Cancer Res 10 3728 3736 15173079 10.1158/1078-0432.CCR-03-0807 1:CAS:528:DC%2BD2cXksVKntrw%3D (Pubitemid 38697606)
15. R Stupp PY Dietrich S Ostermann Kraljevic A Pica I Maillard P Maeder R Meuli R Janzer G Pizzolato R Miralbell F Porchet L Regli N de Tribolet RO Mirimanoff S Leyvraz 2002 Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide J Clin Oncol 20 1375 1382 11870182 10.1200/JCO.20.5.1375 1:CAS:528:DC%2BD38XisVWmu7s%3D (Pubitemid 34177445)
16. R Stupp WP Mason MJ van den Bent M Weller B Fisher MJ Taphoorn K Belanger AA Brandes C Marosi U Bogdahn J Curschmann RC Janzer SK Ludwin T Gorlia A Allgeier D Lacombe JG Cairncross E Eisenhauer RO Mirimanoff 2005 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987 996 15758009 10.1056/NEJMoa043330 1:CAS:528:DC%2BD2MXit1Wksbk%3D (Pubitemid 40349501)
17. R Stupp ME Hegi WP Mason MJ van den Bent MJ Taphoorn RC Janzer SK Ludwin A Allgeier B Fisher K Belanger P Hau AA Brandes J Gijtenbeek C Marosi CJ Vecht K Mokhtari P Wesseling S Villa E Eisenhauer T Gorlia M Weller D Lacombe JG Cairncross RO Mirimanoff 2009 Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol 10 459 466 19269895 10.1016/S1470-2045(09)70025-7 1:CAS:528: DC%2BD1MXlsVKhs74%3D
18. KA Jaeckle KR Hess WK Yung H Greenberg H Fine D Schiff IF Pollack J Kuhn K Fink M Mehta T Cloughesy MK Nicholas S Chang M Prados 2003 Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study J Clin Oncol 21 2305 2311 12805331 10.1200/JCO.2003.12.097 1:CAS:528: DC%2BD2cXpsVKjsrg%3D (Pubitemid 46621868)
19. N Butowski MD Prados KR Lamborn DA Larson PK Sneed WM Wara M Malec J Rabbitt M Page SM Chang 2005 A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma Int J Radiat Oncol Biol Phys 61 1454 1459 15817350 10.1016/j.ijrobp.2004.08.023 1:CAS:528:DC%2BD2MXjtV2ju7k%3D (Pubitemid 40470428)
20. BW Corn DM Yousem CB Scott M Rotman SO Asbell DF Nelson L Martin WJ Curran Jr. 1994 White matter changes are correlated significantly with radiation dose. Observations from a randomized dose-escalation trial for malignant glioma (Radiation Therapy Oncology Group 83-02) Cancer 74 2828 2835 7954244 10.1002/1097-0142(19941115)74:10<2828::AID-CNCR2820741014>3.0.CO;2-K 1:STN:280:DyaK2M%2Fkt1Wgsw%3D%3D (Pubitemid 24340551)
21. JR Crossen D Garwood E Glatstein EA Neuwelt 1994 Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy J Clin Oncol 12 627 642 8120563 1:STN:280:DyaK2c7msFOjsg%3D%3D (Pubitemid 24079908)
22. MR Gilbert HS Friedman JF Kuttesch MD Prados JJ Olson GH Reaman SL Zaknoen 2002 A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy Neuro Oncol 4 261 267 12356356 1:CAS:528:DC%2BD38XotVSmt7Y%3D
23. W Wick C Hartmann C Engel M Stoffels J Felsberg F Stockhammer MC Sabel S Koeppen R Ketter R Meyermann M Rapp C Meisner RD Kortmann T Pietsch OD Wiestler U Ernemann M Bamberg G Reifenberger A von Deimling M Weller 2009 NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide J Clin Oncol 27 5874 5880 19901110 10.1200/JCO.2009.23.6497 1:CAS:528:DC%2BC3cXhtVWis7g%3D
24. DN Louis H Ohgaki OD Wiestler WK Cavenee PC Burger A Jouvet BW Scheithauer P Kleihues 2007 The 2007 WHO classification of tumours of the central nervous system Acta Neuropathol (Berl) 114 97 109 10.1007/s00401-007- 0243-4 (Pubitemid 47103521)
25. DR Macdonald TL Cascino SC Schold Jr. JG Cairncross 1990 Response criteria for phase II studies of supratentorial malignant glioma J Clin Oncol 8 1277 1280 2358840 1:STN:280:DyaK3c3ptlyitQ%3D%3D (Pubitemid 20195640)
26. M Esteller SR Hamilton PC Burger SB Baylin JG Herman 1999 Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia Cancer Res 59 793 797 10029064 1:CAS:528:DyaK1MXht1Sjurk%3D (Pubitemid 29086728)
27. W Mueller M Mizoguchi E Silen K D'Amore CL Nutt DN Louis 2005 Mutations of the PIK3CA gene are rare in human glioblastoma Acta Neuropathol 109 654 655 15924252 10.1007/s00401-005-1001-0 (Pubitemid 40974155)
28. J Jeuken S Cornelissen S Boots-Sprenger S Gijsen P Wesseling 2006 Multiplex ligation-dependent probe amplification: a diagnostic tool for simultaneous identification of different genetic markers in glial tumors J Mol Diagn 8 433 443 16931583 10.2353/jmoldx.2006.060012 1:CAS:528: DC%2BD28XpvFClurw%3D (Pubitemid 44377925)
29. J Balss J Meyer W Mueller A Korshunov C Hartmann A von Deimling 2008 Analysis of the IDH1 codon 132 mutation in brain tumors Acta Neuropathol 116 597 602 18985363 10.1007/s00401-008-0455-2 1:CAS:528:DC%2BD1cXhtlyhsbfN
30. MJ van den Bent HJ Dubbink M Sanson CR van der Lee-Haarloo M Hegi JW Jeuken A Ibdaih AA Brandes MJ Taphoorn M Frenay D Lacombe T Gorlia WN Dinjens JM Kros 2009 MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951 J Clin Oncol 27 5881 5886 19901104 10.1200/JCO.2009.24.1034
31. AA Brandes A Tosoni G Cavallo M Reni E Franceschi L Bonaldi R Bertorelle M Gardiman C Ghimenton P Iuzzolino A Pession V Blatt M Ermani 2006 Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study J Clin Oncol 24 4746 4753 16954518 10.1200/JCO.2006.06.3891 1:CAS:528:DC%2BD28XhtFynsr3E (Pubitemid 46630938)
32. MC Kouwenhoven JM Kros PJ French EM Biemondter Stege WJ Graveland MJ Taphoorn AA Brandes MJ van den Bent 2006 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment Eur J Cancer 42 2499 2503 16914310 10.1016/j.ejca.2006.05.021 1:CAS:528:DC%2BD28XhtVagtrfM (Pubitemid 44468379)
33. CA Griffin P Burger L Morsberger R Yonescu S Swierczynski JD Weingart KM Murphy 2006 Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss J Neuropathol Exp Neurol 65 988 994 17021403 10.1097/01.jnen.0000235122.98052.8f (Pubitemid 44521799)
34. RB Jenkins H Blair KV Ballman C Giannini RM Arusell M Law H Flynn S Passe S Felten PD Brown EG Shaw JC Buckner 2006 A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma Cancer Res 66 9852 9861 17047046 10.1158/0008-5472.CAN- 06-1796 1:CAS:528:DC%2BD28XhtVyiur3I (Pubitemid 44672036)
35. K Ichimura AP Vogazianou L Liu DM Pearson LM Backlund K Plant K Baird CF Langford SG Gregory VP Collins 2008 1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas Oncogene 27 2097 2108 17934521 10.1038/sj.onc.1210848 1:CAS:528:DC%2BD1cXjslWjtrY%3D (Pubitemid 351442746)
36. A Idbaih Y Marie G Pierron C Brennetot K Hoang-Xuan M Kujas K Mokhtari M Sanson J Lejeune A Aurias O Delattre JY Delattre 2005 Two types of chromosome 1p losses with opposite significance in gliomas Ann Neurol 58 483 487 16130103 10.1002/ana.20607 1:CAS:528:DC%2BD2MXhtFWqsr7L (Pubitemid 41266639)
37. C Hartmann L Johnk G Kitange Y Wu LK Ashworth RB Jenkins DN Louis 2002 Transcript map of the 3.7-Mb D19S112-D19S246 candidate tumor suppressor region on the long arm of chromosome 19 Cancer Res 62 4100 4108 12124348 1:CAS:528:DC%2BD38XlsV2lsbc%3D (Pubitemid 34791081)
38. C Hartmann W Mueller U Lass S Kamel-Reid A von Deimling 2005 Molecular genetic analysis of oligodendroglial tumors J Neuropathol Exp Neurol 64 10 14 15715080 1:CAS:528:DC%2BD2MXis1Slsrk%3D (Pubitemid 40189474)
39. HK Gan MA Rosenthal A Dowling R Kalnins E Algar N Wong A Benson A-M Woods L Cher 2010 A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors Neuro Oncol 12 500 507 20406900 1:CAS:528:DC%2BC3cXotVWmtrs%3D